Edison Investment Research - Albioma (SECH) Update: H1 results meet expectations

Report

Edison Investment Research

Update: H1 results meet expectations

The H1 results indicate that Albioma is on track to meet its full-year targets for net income and EBITDA, underpinned by a very strong performance from its new Brazilian assets. The performance of Brazil and the contribution of two new plants scheduled to come into operation in 2016 should help progress towards the companyâ€™s longer-term targets. Our analysis suggests an average valuation for Albioma of c â‚¬22.5/share.

24/07/2014 1 EN

Underlying

Albioma

Albioma is an independent energy producer that develops projects in the thermal biomass, solar power, and anaerobic digestion sectors. Co. provides industrial partners with expertise in energy production via hybrid combustion of biomass. In addition, Co. produces biogas by biological decomposition of organic matter in a confined oxygen-free medium, which it either converts into electricity and heat or purifies and then injects into the gas transmission network. It operates facilities on Reunion Island, Mayotte, Guadeloupe, Martinique, and French Guyana, mainland France and Southern Europe. Co. divides its operation into three segments: Thermal Biomass, Solar Power, and Anaerobic Digestion.

See profile

FR0000060402 Euronext Paris France

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

GlobeNewsWire

Albioma : Press release relating to the squeeze-out procedure for the shares and warrants of Albioma

Albioma : Press release relating to the squeeze-out procedure for the shares and warrants of Albioma PRESS RELEASE DATED SEPTEMBER 29, 2022 RELATING TO THE SQUEEZE-OUT PROCEDURE FOR THE SHARES AND WARRANTS OF ALBIOMA FOLLOWING THE PUBLIC TENDER OFFER INITIATED BY KYOTO BIDCO SAS AMOUNT OF INDEMNIFICATION: 50 euros per Albioma share (ex-dividend) 29,10 euros per Albioma Warrant This press release was prepared and distributed by Kyoto BidCo SAS in accordance with the provisions of Article 237-3 III of the General Regulation of the French Autorité des Marchés Fi...

September 29, 2022 September 29, 2022 1 EN

GlobeNewsWire

ALBIOMA : Communiqué relatif à la mise en œuvre du retrait obligatoire visant les actions et les BSAAR de la société Albioma

ALBIOMA : Communiqué relatif à la mise en œuvre du retrait obligatoire visant les actions et les BSAAR de la société Albioma Ce communiqué ne constitue pas une offre d’acquisition de titres. COMMUNIQUÉ DE PRESSE DU 29 SEPTEMBRE 2022RELATIF À LA MISE EN OEUVRE DU RETRAIT OBLIGATOIRE VISANT LES ACTIONS ET LES BSAAR DE LA SOCIÉTÉ ALBIOMACONSÉCUTIVEMENT À L’OFFRE PUBLIQUE D’ACHATINITIÉE PARKYOTO BIDCO SAS MONTANT DE L’INDEMNISATION : 50 euros par action Albioma (dividende détaché) 29,10 euros par bon de souscription et/ou d’acquisition d’actions remboursables Albioma Le présent communiqué...

September 29, 2022 September 29, 2022 1 EN

Portzamparc Sponsored

La Matinale - 2022-09-15

LA VALEUR DU JOUR : PRODWAYS : Des résultats semestriels exceptionnels / Contact – Acheter (1), obj. 4.00€ Cours: 3.28€ au 14/09/22 ALBIOMA : Vers un retrait de cote Cours: 47.1€ au 14/09/22 CARMAT : Confiant sur la reprise – Acheter (1), obj. 29.0€ Cours: 12.8€ au 14/09/22 ESKER : Un discours (trop?) prudent – Acheter (1), obj. 189.0€ Cours: 131.7€ au 14/09/22 INNATE PHARMA : Horizon de trésorerie confortable et de nouveaux projets à venir – Acheter (1), obj. 6.20€ Cours: 2.58€ au 14/09/22.... LNA SANTE : Résultats S1 en ligne, guidance confirmée – Acheter (1), obj. 46.0€ Cours: 30.0€ au...

September 15, 2022 September 15, 2022 1 FR

Foxtons Group - FY24 underpinned by market share gains

Foxtons Group’s Q1 revenue grew by 9%, supported by growth in all three divisions as the strategic initiatives continue to gain significant momentum, driven by investment in staff, best-in-class bespoke IT and data platforms. This implies that Foxtons’ medium-term targets are now coming into focus. Market share is being gained in all divisions, which puts Foxtons in a good position as the sales market stabilises. We maintain our valuation of 132p/share and believe that if interest rates stabilise or ease further, there are upside risks to our forecasts.

35m 35m 1 EN

Pedro Fonseca

Pedro Fonseca

Manx Financial Group - Executing on a high-growth strategy

Manx Financial Group (Manx) posted record PBT of £7m, a 35% increase year-on-year. Manx benefited from strong volumes, a full year contribution from Payment Assist Limited (PAL) and a £1.9m gain on debt securities, which offset funding cost pressures from higher average interest rates. Alongside a 24% increase in lending to £362.7m, it maintained robust credit quality, with its cost of risk (CoR) decreasing by 20bp y-o-y to 1.3%. As a result, the group delivered a strong return on average equity (RoAE) of 16.4%, 50bp higher than FY22. In line with its 10% dividend payout policy, the group prop...

2h / 26m 2h / 26m 1 EN

Toby Thorrington

Toby Thorrington

Carr's Group - An enhanced value creation strategy

Carr’s Group has announced an updated strategy that offers the potential for value realisation and creation from a number of avenues. These include: value realisation of the Engineering Division; the ability to significantly reduce central costs; and longer-term value creation in the Agriculture Division as a focused business with recovery potential and a strategy to leverage its strong market positions for growth.

3h / 48m 3h / 48m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN